iX Biopharma Ltd. (SG:42C) has released an update.
iX Biopharma Ltd. has announced the formation of a new Audit and Risk Committee by merging its Audit Committee and Risk Management Committee. This restructuring aims to streamline the roles and responsibilities of its board members, enhancing governance efficiency. Additionally, the company has reconstituted its board committees following the retirement of Independent Director Ms. Angeline Tham.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.